drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Base-edited, allogeneic anti-CD33 chimeric antigen receptor (CAR) T-cell therapy. Donor T cells are engineered with a CD33-specific CAR and base edits to enable function after chemotherapy and reduce alloreactivity/off-tumor effects (e.g., lower GVHD risk). Administered as a single IV infusion prior to allo-HSCT to target CD33+ AML blasts.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Base-edited, allogeneic T cells expressing a CD33-specific chimeric antigen receptor bind CD33 on AML blasts and induce targeted cytotoxicity via T-cell activation (perforin/granzyme release, cytokines, and death-receptor pathways). Base edits reduce TCR-driven alloreactivity and off-tumor effects and are intended to enable persistence/function after conditioning chemotherapy. Administered as a single IV infusion prior to allo-HSCT.
drug_name
Cryopreserved BE CAR33 T Cells (BE752TBTTBCAR33PBL)
nct_id_drug_ref
NCT05942599